Company news
Microba Life Sciences Limited (ASX:MAP) news
Microba Life Sciences Limited news releases on 6ix. Latest, Nov 28, 2023: Autoimmune Stage 1 Screening Complete with Gingko Bioworks
Press releases — page 2
Autoimmune Stage 1 Screening Complete with Gingko Bioworks
November 27, 2023
Results of Retail Entitlement Offer
November 19, 2023
Fully Underwritten A$20 million Entitlement Offer
October 22, 2023
Invivo Clinical Acquisition and Capital Raising Presentation
October 18, 2023
Microba to acquire UK microbiome leader Invivo Clinical
October 18, 2023
Q1 FY24 Quarterly Activities Report & Appendix 4C
October 18, 2023
Appendix 4E & Annual Report
August 29, 2023
Q4 FY23 Quarterly Investor Presentation
July 26, 2023
Q4 FY23 Quarterly Activities Report & Appendix 4C
July 26, 2023
First Distribution Agreement Executed with Sonic Healthcare
July 4, 2023
Microba Commences Phase I Clinical Trial for IBD Therapeutic
June 27, 2023
MRFF Grant Awarded to QUT, In Collaboration With Microba
June 27, 2023
Microba receives two AusIndustry Advanced Overseas Findings
June 14, 2023
Q3 FY23 Quarterly Investor Presentation
April 19, 2023
Q3 FY23 Quarterly Activities Report & Appendix 4C
April 19, 2023
SYNLAB Contracts Signed in Poland, Hungary, Romania, Croatia
April 12, 2023
Microba Receives Ethics Approval for Phase 1 Clinical Trial
March 29, 2023
SYNLAB Agreements Signed in Turkiye and Czech Republic
March 1, 2023
Microba Launches Next Generation Healthcare Testing
February 27, 2023
H1 FY23 Interim Report
February 22, 2023
US Distribution Agreement Signed with Luminary Health
February 6, 2023
Positive first animal data for Cancer Program
January 31, 2023
Q2 FY23 Quarterly Activities Report & Appendix 4C
January 29, 2023
SYNLAB Agreements Signed in Italy and Portugal
December 7, 2022
Sonic Investment & Partnership Investor Presentation
November 28, 2022
Sonic Acquires 19.9% Microba Stake and Enters Partnership
November 28, 2022
Microba receives $2.62m R&D Tax Incentive refund
October 31, 2022
Q1 FY23 Quarterly Activities Report & Appendix 4C
October 26, 2022
Microba, SYNLAB Extend & Expand Distribution
October 19, 2022
Therapeutic Program Advancement
August 30, 2022
Investor Presentation - FY22 Update Annual Results
August 29, 2022
Q4 FY22 Quarterly Activities Report & Appendix 4C
July 19, 2022
G42 Healthcare Partnership Commences Operation
June 27, 2022
Microba & Ginkgo Commence Therapeutics Program
June 7, 2022
Partnership signed with nib-backed Midnight Health
May 25, 2022
Microba Accelerates Cancer Program
May 5, 2022